Ex nihilo: Takeda leads $100M+ round to fund biotech's sneak attack on tumors, propelling new IL-2, CTLA-4 drugs to clinic
Since emerging out of stealth in 2018 with $30 million in launch money from Atlas and F-Prime, Akrevia has kept a relatively low profile, hammering away at its platform technology to design immunotherapies with all their potency but little of their side effects. With an official CEO in place for almost a year — and now a new name — the biotech is ready to step up with another $100.5 million to bring its two lead compounds into the clinic.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.